Bridgewater-based Sanofi and Regeneron Pharmaceuticals announced Monday Praluent (alirocumab) will be made available at a new U.S. list price of $5,850 annually, a 60 percent reduction from the original price, for both the 75 mg and 150 mg doses, beginning in early March.
Praluent lowers LDL (bad) cholesterol.
In a press release Sanofi said that this is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients.
According to Sanofi, with the new lower-priced Praluent, most Medicare Part D patients are expected to pay between $25 to $150 per month, a potential savings of up to $345, depending on their insurance plan. Eligible commercial patients will continue to have access to copay assistance through MyPraluent.
For illustrative purposes only, this calculation of monthly savings assumes a scenario where Praluent is on a specialty tier with 33 percent co-insurance and Praluent then moves to preferred brand tier co-pay of $25. Individual savings will vary according to plan.
“In 2018, we lowered the Praluent net price for health plans that were willing to improve patient access and affordability. While lowering the net cost to payers did improve access, seniors who were prescribed Praluent were often still unable to afford it due to high co-pay costs or co-insurance at many Medicare Part D plans,” said Dr. Leonard Schleifer, president and CEO Regeneron. “Offering a lower-priced Praluent will help lower seniors’ out-of-pocket costs and thereby remove another barrier to receiving this important medicine.”
The new, lower-priced Praluent is expected to be available for pharmacies to order in early March, and the doses with the original list price will remain on the market at least through 2019. The lower-priced Praluent will be identical to the Praluent currently available, other than the list price.
Praluent was developed by Regeneron and Sanofi under a global collaboration agreement.